All In MedTech

Device Trial Radar · NCT04795752

Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

Prospective, Randomized, Masked, Controlled Trial To Evaluate The Safety And Effectiveness Of The TearCare® System In The Treatment Of The Signs And Symptoms Of Dry Eye Disease (SAHARA)

Last checked: Nov 19, 2026Latest source record: Nov 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 345 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

345

Actual

Start

Apr 28, 2021

Primary completion

Sep 23, 2024

Study completion Sep 23, 2024

Sponsor

Lead sponsor
Sight Sciences, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Mar 12, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To demonstrate the safety and effectiveness of TearCare® procedures compared to Restasis® to treat the signs and symptoms of dry eye disease in adult patients.

Conditions

  • Dry Eye
  • Meibomian Gland Dysfunction

Interventions

  • TearCare SystemDevice

    TearCare procedures in this study will include an in-office eyelid debridement, 15 minute bilateral thermal session with the TearCare System, immediately followed by manual expression of the meibomian glands using the Clearance Assistant Plus device. Subjects randomized to TearCare will receive one in-office TearCare procedure within 7 days of the Baseline visit and at 5 Months.

  • Cyclosporine Ophthalmic 0.05% Ophthalmic EmulsionDrug

    Restasis group will be required to self-administer 1 drop twice a day from baseline through the Month 6 visit. At the Month 6 visit subjects will stop Restasis and receive a single TearCare treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tear Break-Up TimeTime frame: 6 months
  2. OSDI ScoreTime frame: 6 months

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Doctor My Eyes

    Scottsdale, Arizona

  • Scripps Health

    La Jolla, California

  • Harvard Eye Associates

    Laguna Hills, California

11 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.